New kid on the block: Roger Perlmutter’s biotech signs on as anchor tenant to new Bay Area campus

Having left behind a stellar legacy in Merck’s headquarters in Kenilworth, NJ, Roger Perlmutter’s next chapter of drug R&D will be written in the San Francisco Bay Area.

Eikon Therapeutics, the ambitious biotech startup helmed by Perlmutter, has signed a long-term lease to set up its new corporate headquarters...

Click to view original post